MUC16 and ovarian cancer: The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) conducted studies of annual multimodal screening (longitudinal CA125 and second-line TVS) as well as annual TVS screenings (TVS first- and second-line tests) and found that the CA125 test screen allowed for a subtle stage shift, with stage I and stage IV cancer incidence 47.2% higher and 24.5% lower, respectively, compared with an unscreened group.